Literature DB >> 16645980

Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation.

Petra Zürbig1, Matthew B Renfrow, Eric Schiffer, Jan Novak, Michael Walden, Stefan Wittke, Ingo Just, Matthias Pelzing, Christian Neusüss, Dan Theodorescu, Karen E Root, Mark M Ross, Harald Mischak.   

Abstract

CE-MS is a successful proteomic platform for the definition of biomarkers in different body fluids. Besides the biomarker defining experimental parameters, CE migration time and molecular weight, especially biomarker's sequence identity is an indispensable cornerstone for deeper insights into the pathophysiological pathways of diseases or for made-to-measure therapeutic drug design. Therefore, this report presents a detailed discussion of different peptide sequencing platforms consisting of high performance separation method either coupled on-line or off-line to different MS/MS devices, such as MALDI-TOF-TOF, ESI-IT, ESI-QTOF and Fourier transform ion cyclotron resonance, for sequencing indicative peptides. This comparison demonstrates the unique feature of CE-MS technology to serve as a reliable basis for the assignment of peptide sequence data obtained using different separation MS/MS methods to the biomarker defining parameters, CE migration time and molecular weight. Discovery of potential biomarkers by CE-MS enables sequence analysis via MS/MS with platform-independent sample separation. This is due to the fact that the number of basic and neutral polar amino acids of biomarkers sequences distinctly correlates with their CE-MS migration time/molecular weight coordinates. This uniqueness facilitates the independent entry of different sequencing platforms for peptide sequencing of CE-MS-defined biomarkers from highly complex mixtures.

Mesh:

Substances:

Year:  2006        PMID: 16645980     DOI: 10.1002/elps.200500827

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  55 in total

Review 1.  Mass spectrometry based proteomics in urine biomarker discovery.

Authors:  Dan Theodorescu; Harald Mischak
Journal:  World J Urol       Date:  2007-08-17       Impact factor: 4.226

Review 2.  Proteomic biomarkers in kidney disease: issues in development and implementation.

Authors:  Harald Mischak; Christian Delles; Antonia Vlahou; Raymond Vanholder
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

3.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

4.  Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Marion Haubitz; David M Good; Alexander Woywodt; Hermann Haller; Harald Rupprecht; Dan Theodorescu; Mohammed Dakna; Joshua J Coon; Harald Mischak
Journal:  Mol Cell Proteomics       Date:  2009-06-28       Impact factor: 5.911

5.  Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.

Authors:  Constantin von zur Muhlen; Eric Schiffer; Christine Sackmann; Petra Zürbig; Irene Neudorfer; Andreas Zirlik; Nay Htun; Alexander Iphöfer; Lothar Jänsch; Harald Mischak; Christoph Bode; Yung C Chen; Karlheinz Peter
Journal:  Mol Cell Proteomics       Date:  2012-02-27       Impact factor: 5.911

6.  The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.

Authors:  Petra Zürbig; Stéphane Decramer; Mohammed Dakna; Justyna Jantos; David M Good; Joshua J Coon; Flavio Bandin; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

7.  Application of Proteomic Analysis to Renal Disease in the Clinic.

Authors:  Bruce A Julian; Hitoshi Suzuki; Goce Spasovski; Yusuke Suzuki; Yasuhiko Tomino; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2009-01-01       Impact factor: 3.494

8.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Authors:  Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Journal:  BMC Nephrol       Date:  2010-11-01       Impact factor: 2.388

9.  Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.

Authors:  David M Maahs; Justyna Siwy; Angel Argilés; Marie Cerna; Christian Delles; Anna F Dominiczak; Nathalie Gayrard; Alexander Iphöfer; Lothar Jänsch; George Jerums; Karel Medek; Harald Mischak; Gerjan J Navis; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Eric Schiffer; Roland E Schmieder; Thomas C Wascher; Brigitte M Winklhofer-Roob; Lukas U Zimmerli; Petra Zürbig; Janet K Snell-Bergeon
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

10.  Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease.

Authors:  Hong Jiang; Eric Schiffer; Zhangfa Song; Jianwei Wang; Petra Zürbig; Kathrin Thedieck; Suzette Moes; Heike Bantel; Nadja Saal; Justyna Jantos; Meiken Brecht; Paul Jenö; Michael N Hall; Klaus Hager; Michael P Manns; Hartmut Hecker; Arnold Ganser; Konstanze Döhner; Andrzej Bartke; Christoph Meissner; Harald Mischak; Zhenyu Ju; K Lenhard Rudolph
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.